Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

NCT02346084 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV/AIDS

Interventions

DRUG: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)

Sponsor

International Partnership for Microbicides, Inc.

Collaborators

[object Object]
[object Object]